Acute Leukemia, 42 patients

treatment (1 = Treated <6-mercatopurine>, 0 = Placebo)
time of remission in weeks
status (0 = censored, 1 = relapsed)

ref = Reference Freireich et al. Blood 21(1963): 699-716.
Note: trial was conducted by matching pairs of patients by remission status, and randomizing with pairs to treatment or placebo. We ignore this pairing in our analysis.

 

0 1 1
0 1 1
0 2 1
0 2 1
0 3 1
0 4 1
0 4 1
0 5 1
0 5 1
0 8 1
0 8 1
0 8 1
0 8 1
0 11 1
0 11 1
0 12 1
0 12 1
0 15 1
0 17 1
0 22 1
0 23 1
1 6 1
1 6 1
1 6 1
1 6 0
1 7 1
1 9 0
1 10 1
1 10 0
1 11 0
1 13 1
1 16 1
1 17 0
1 19 0
1 20 0
1 22 1
1 23 1
1 25 0
1 32 0
1 32 0
1 34 0
1 35 0

######################

Ovarian cancer data, 35 patients (stage II/IIIA)

grade of tumor (0 = low, 1 = high)

time to progression in days

status (0 = censored, 1 = progressed)

ref = Fleming TR, O'Fallen JR, O'Brien PC, Harrington DP. Biometrics 36:607-625, 1979

0 28 1
0 89 1
0 175 1
0 195 1
0 309 1
0 377 0
0 393 0
0 421 0
0 447 0
0 462 1
0 709 0
0 744 0
0 770 0
0 1106 0
0 1206 0
1 34 1
1 88 1
1 137 1
1 199 1
1 280 1
1 291 1
1 299 0
1 300 0
1 309 1
1 351 1
1 358 1
1 369 1
1 369 1
1 370 1
1 375 1
1 382 1
1 392 1
1 429 0
1 451 1
1 1119 0

#################################

Gastric Cancer Data, 90 patients

treatment (0= chemo alone, 1 = chemo + radiation)

survival in days

status (0 = censored, 1 = death)

ref = Stablein DM, Carter WH, Novak JW. Controlled Clinical Trials 2:149-159, 1981.

1 17 1
1 42 1
1 44 1
1 48 1
1 60 1
1 72 1
1 74 1
1 95 1
1 103 1
1 108 1
1 122 1
1 144 1
1 167 1
1 170 1
1 183 1
1 185 1
1 193 1
1 195 1
1 197 1
1 208 1
1 234 1
1 235 1
1 254 1
1 307 1
1 315 1
1 401 1
1 445 1
1 464 1
1 484 1
1 528 1
1 542 1
1 567 1
1 577 1
1 580 1
1 795 1
1 855 1
1 882 0
1 892 0
1 1031 0
1 1033 0
1 1306 0
1 1335 0
1 1366 1
1 1452 0
1 1472 0
0 1 1
0 63 1
0 105 1
0 129 1
0 182 1
0 216 1
0 250 1
0 262 1
0 301 1
0 301 1
0 342 1
0 354 1
0 356 1
0 358 1
0 380 1
0 381 0
0 383 1
0 383 1
0 388 1
0 394 1
0 408 1
0 460 1
0 489 1
0 499 1
0 524 1
0 529 0
0 535 1
0 562 1
0 675 1
0 676 1
0 748 1
0 748 1
0 778 1
0 786 1
0 797 1
0 945 0
0 955 1
0 968 1
0 1180 0
0 1245 1
0 1271 1
0 1277 0
0 1397 0
0 1512 0
0 1519 0

#############################

bileduct cancer - 47 patients

treatment with radiation+chemotherapy

group (0 = control, 1 = treated)

time (survival in days)

status (0 = censored, 1 = death)

ref = Fleming TR, O'Fallen JR, O'Brien PC, Harrington DP. Biometrics 36:607-625, 1979

 

1 30 1

1 67 1

1 79 0

1 82 0

1 95 1

1 148 1

1 170 1

1 171 1

1 176 1

1 193 1

1 200 1

1 221 1

1 243 1

1 261 1

1 262 1

1 263 1

1 399 1

1 414 1

1 446 0

1 446 1

1 464 1

1 777 1

0 57 1

0 58 1

0 74 1

0 79 1

0 89 1

0 98 1

0 101 1

0 104 1

0 110 1

0 118 1

0 125 1

0 132 1

0 154 1

0 159 1

0 188 1

0 203 1

0 257 1

0 257 1

0 431 1

0 461 1

0 497 1

0 723 1

0 747 1

0 1313 1

0 2636 1

#############################

The following datasets come from the website for "Survival Analysis:

Techniques for Censored

and Truncated Data" by John Klein and Melvin Moeschberger, Springer, 1997

http://www.biostat.mcw.edu/homepgs/klein/menu.html

##################

Data on 119 kidney dialysis patients - see Section 1.4

Time to infection, months

Infection indicator (0=no, 1=yes)

Catheter placement (1=surgically, 2=percutaneously)

Reference: Nahman el at. J. Am Soc. Nephrology 3 (1992): 103-107.

1.5 1 1

3.5 1 1

4.5 1 1

4.5 1 1

5.5 1 1

8.5 1 1

8.5 1 1

9.5 1 1

10.5 1 1

11.5 1 1

15.5 1 1

16.5 1 1

18.5 1 1

23.5 1 1

26.5 1 1

2.5 0 1

2.5 0 1

3.5 0 1

3.5 0 1

3.5 0 1

4.5 0 1

5.5 0 1

6.5 0 1

6.5 0 1

7.5 0 1

7.5 0 1

7.5 0 1

7.5 0 1

8.5 0 1

9.5 0 1

10.5 0 1

11.5 0 1

12.5 0 1

12.5 0 1

13.5 0 1

14.5 0 1

14.5 0 1

21.5 0 1

21.5 0 1

22.5 0 1

22.5 0 1

25.5 0 1

27.5 0 1

0.5 1 2

0.5 1 2

0.5 1 2

0.5 1 2

0.5 1 2

0.5 1 2

2.5 1 2

2.5 1 2

3.5 1 2

6.5 1 2

15.5 1 2

0.5 0 2

0.5 0 2

0.5 0 2

0.5 0 2

0.5 0 2

0.5 0 2

0.5 0 2

0.5 0 2

0.5 0 2

0.5 0 2

1.5 0 2

1.5 0 2

1.5 0 2

1.5 0 2

2.5 0 2

2.5 0 2

2.5 0 2

2.5 0 2

2.5 0 2

3.5 0 2

3.5 0 2

3.5 0 2

3.5 0 2

3.5 0 2

4.5 0 2

4.5 0 2

4.5 0 2

5.5 0 2

5.5 0 2

5.5 0 2

5.5 0 2

5.5 0 2

6.5 0 2

7.5 0 2

7.5 0 2

7.5 0 2

8.5 0 2

8.5 0 2

8.5 0 2

9.5 0 2

9.5 0 2

10.5 0 2

10.5 0 2

10.5 0 2

11.5 0 2

11.5 0 2

12.5 0 2

12.5 0 2

12.5 0 2

12.5 0 2

14.5 0 2

14.5 0 2

16.5 0 2

16.5 0 2

18.5 0 2

19.5 0 2

19.5 0 2

19.5 0 2

20.5 0 2

22.5 0 2

24.5 0 2

25.5 0 2

26.5 0 2

26.5 0 2

28.5 0 2

#################################

Data on 45 females with node-negative breast cancer - Section 1.5

Time to death or on-study time, months

Death indicator (0=alive, 1=dead)

Immunohistochemical response (1=negative, 2=positive)

Reference Sedmak el al. Modern Pathology 2 (1989): 516-520.

19 1 1

25 1 1

30 1 1

34 1 1

37 1 1

46 1 1

47 1 1

51 1 1

56 1 1

57 1 1

61 1 1

66 1 1

67 1 1

74 1 1

78 1 1

86 1 1

122 0 1

123 0 1

130 0 1

130 0 1

133 0 1

134 0 1

136 0 1

141 0 1

143 0 1

148 0 1

151 0 1

152 0 1

153 0 1

154 0 1

156 0 1

162 0 1

164 0 1

165 0 1

182 0 1

189 0 1

22 1 2

23 1 2

38 1 2

42 1 2

73 1 2

77 1 2

89 1 2

115 1 2

144 0 2

##########################################

Data on 90 males with larynx cancer - Section 1.8

Stage of disease (1=stage 1, 2=stage2, 3=stage 3, 4=stage 4)

Time to death or on-study time, months

Age at diagnosis of larynx cancer

Year of diagnosis of larynx cancer

Death indicator (0=alive, 1=dead)

Reference: Kardaun Stat. Nederlandica 37 (1983), 103-126.

1 0.6 77 76 1

1 1.3 53 71 1

1 2.4 45 71 1

1 2.5 57 78 0

1 3.2 58 74 1

1 3.2 51 77 0

1 3.3 76 74 1

1 3.3 63 77 0

1 3.5 43 71 1

1 3.5 60 73 1

1 4 52 71 1

1 4 63 76 1

1 4.3 86 74 1

1 4.5 48 76 0

1 4.5 68 76 0

1 5.3 81 72 1

1 5.5 70 75 0

1 5.9 58 75 0

1 5.9 47 75 0

1 6 75 73 1

1 6.1 77 75 0

1 6.2 64 75 0

1 6.4 77 72 1

1 6.5 67 70 1

1 6.5 79 74 0

1 6.7 61 74 0

1 7 66 74 0

1 7.4 68 71 1

1 7.4 73 73 0

1 8.1 56 73 0

1 8.1 73 73 0

1 9.6 58 71 0

1 10.7 68 70 0

2 0.2 86 74 1

2 1.8 64 77 1

2 2 63 75 1

2 2.2 71 78 0

2 2.6 67 78 0

2 3.3 51 77 0

2 3.6 70 77 1

2 3.6 72 77 0

2 4 81 71 1

2 4.3 47 76 0

2 4.3 64 76 0

2 5 66 76 0

2 6.2 74 72 1

2 7 62 73 1

2 7.5 50 73 0

2 7.6 53 73 0

2 9.3 61 71 0

3 0.3 49 72 1

3 0.3 71 76 1

3 0.5 57 74 1

3 0.7 79 77 1

3 0.8 82 74 1

3 1 49 76 1

3 1.3 60 76 1

3 1.6 64 72 1

3 1.8 74 71 1

3 1.9 72 74 1

3 1.9 53 74 1

3 3.2 54 75 1

3 3.5 81 74 1

3 3.7 52 77 0

3 4.5 66 76 0

3 4.8 54 76 0

3 4.8 63 76 0

3 5 59 73 1

3 5 49 76 0

3 5.1 69 76 0

3 6.3 70 72 1

3 6.4 65 72 1

3 6.5 65 74 0

3 7.8 68 72 1

3 8 78 73 0

3 9.3 69 71 0

3 10.1 51 71 0

4 0.1 65 72 1

4 0.3 71 76 1

4 0.4 76 77 1

4 0.8 65 76 1

4 0.8 78 77 1

4 1 41 77 1

4 1.5 68 73 1

4 2 69 76 1

4 2.3 62 71 1

4 2.9 74 78 0

4 3.6 71 75 1

4 3.8 84 74 1

4 4.3 48 76 0

####################################

Data on acute leukemia, 101 patients - Section 1.9

Time to death or relapse, months

Type of transplant (1=allogeneic, 2=autologous)

Leukemia-free survival indicator (0=alive without relapse, 1=dead or relapse)

Reference = pg 10 of Klein & Moeschberger, no original ref given

0.030 1 1

0.493 1 1

0.855 1 1

1.184 1 1

1.283 1 1

1.480 1 1

1.776 1 1

2.138 1 1

2.500 1 1

2.763 1 1

2.993 1 1

3.224 1 1

3.421 1 1

4.178 1 1

4.441 1 0

5.691 1 1

5.855 1 0

6.941 1 0

6.941 1 1

7.993 1 0

8.882 1 1

8.882 1 1

9.145 1 0

11.480 1 1

11.513 1 1

12.105 1 0

12.796 1 1

12.993 1 0

13.849 1 0

16.612 1 0

17.138 1 0

20.066 1 1

20.329 1 0

22.368 1 0

26.776 1 0

28.717 1 0

28.717 1 0

32.928 1 1

33.783 1 0

34.221 1 0

34.770 1 0

39.593 1 0

41.118 1 0

45.003 1 0

46.053 1 0

46.941 1 0

48.289 1 0

57.401 1 0

58.322 1 0

60.625 1 0

0.658 2 1

0.822 2 1

1.414 2 1

2.500 2 1

3.322 2 1

3.816 2 1

4.737 2 1

4.836 2 0

4.934 2 1

5.033 2 1

5.757 2 1

5.855 2 1

5.987 2 1

6.151 2 1

6.217 2 1

6.447 2 0

8.651 2 1

8.711 2 1

9.441 2 0

10.329 2 1

11.480 2 1

12.007 2 1

12.007 2 0

12.237 2 1

12.401 2 0

13.059 2 0

14.474 2 0

15.000 2 0

15.461 2 1

15.757 2 1

16.480 2 1

16.711 2 1

17.204 2 0

17.237 2 1

17.303 2 0

17.664 2 0

18.092 2 1

18.092 2 0

18.750 2 0

20.625 2 0

23.158 2 1

27.730 2 0

31.184 2 0

32.434 2 0

35.921 2 0

42.237 2 0

44.638 2 0

46.480 2 0

47.467 2 0

48.322 2 0

56.086 2 1

#################################################

Data of 80 males diagnosed with cancer of the tongue - Section 1.11

Tumor DNA profile (1=Aneuploid Tumor, 2=Diploid Tumor)

Time to death or on-study time, weeks

Death indicator (0=alive, 1=dead)

Reference Sickle-Santanello et al. Cytometry 9 (1988): 594-599.

1 1 1

1 3 1

1 3 1

1 4 1

1 10 1

1 13 1

1 13 1

1 16 1

1 16 1

1 24 1

1 26 1

1 27 1

1 28 1

1 30 1

1 30 1

1 32 1

1 41 1

1 51 1

1 65 1

1 67 1

1 70 1

1 72 1

1 73 1

1 77 1

1 91 1

1 93 1

1 96 1

1 100 1

1 104 1

1 157 1

1 167 1

1 61 0

1 74 0

1 79 0

1 80 0

1 81 0

1 87 0

1 87 0

1 88 0

1 89 0

1 93 0

1 97 0

1 101 0

1 104 0

1 108 0

1 109 0

1 120 0

1 131 0

1 150 0

1 231 0

1 240 0

1 400 0

2 1 1

2 3 1

2 4 1

2 5 1

2 5 1

2 8 1

2 12 1

2 13 1

2 18 1

2 23 1

2 26 1

2 27 1

2 30 1

2 42 1

2 56 1

2 62 1

2 69 1

2 104 1

2 104 1

2 112 1

2 129 1

2 181 1

2 8 0

2 67 0

2 76 0

2 104 0

2 176 0

2 231 0